Hongmei Zhu1, Siu Wai Leung. 1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macao, 999078, China.
Abstract
AIMS/HYPOTHESIS: The aim was to identify potential microRNA (miRNA) biomarkers of type 2 diabetes. METHODS: Controlled studies were retrieved from PubMed to compare miRNA expression profiles of type 2 diabetes and nondiabetic control samples. Meta-analysis under a random effects model was conducted. Subgroup analyses examined tissue specificity and species specificity. Sensitivity analyses were also performed to explain the heterogeneity among studies. Results were represented as log odds ratios (logOR), 95% confidence intervals (CI) and p values after Bonferroni correction. RESULTS: Among 343 differentially expressed miRNAs in 38 miRNA expression profiling studies published between 1993 and March 2014, only 151 miRNAs were tested by multiple studies, out of which 102 miRNAs were reported to be upregulated or downregulated. Meta-analysis identified 51 significantly dysregulated miRNAs. The top upregulated miRNA was miR-142-3p (logOR 6.4721; 95% CI 4.9537, 7.9904; adjusted p = 4.60 × 10(-16)). The top downregulated miRNA was miR-126a (logOR 7.5237; 95% CI 4.7159, 10.3316; adjusted p = 3.01 × 10(-07)). The dysregulation of two miRNAs (miR-199a-3p and miR-223) was highly pancreas-specific and liver-specific. miR-30e was downregulated in patients with type 2 diabetes, while miR-92a was downregulated in animal models of diabetes. In sensitivity analysis, 40 out of 47 miRNAs (85%) were robustly and consistently dysregulated. CONCLUSIONS/ INTERPRETATION: This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375, miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
AIMS/HYPOTHESIS: The aim was to identify potential microRNA (miRNA) biomarkers of type 2 diabetes. METHODS: Controlled studies were retrieved from PubMed to compare miRNA expression profiles of type 2 diabetes and nondiabetic control samples. Meta-analysis under a random effects model was conducted. Subgroup analyses examined tissue specificity and species specificity. Sensitivity analyses were also performed to explain the heterogeneity among studies. Results were represented as log odds ratios (logOR), 95% confidence intervals (CI) and p values after Bonferroni correction. RESULTS: Among 343 differentially expressed miRNAs in 38 miRNA expression profiling studies published between 1993 and March 2014, only 151 miRNAs were tested by multiple studies, out of which 102 miRNAs were reported to be upregulated or downregulated. Meta-analysis identified 51 significantly dysregulated miRNAs. The top upregulated miRNA was miR-142-3p (logOR 6.4721; 95% CI 4.9537, 7.9904; adjusted p = 4.60 × 10(-16)). The top downregulated miRNA was miR-126a (logOR 7.5237; 95% CI 4.7159, 10.3316; adjusted p = 3.01 × 10(-07)). The dysregulation of two miRNAs (miR-199a-3p and miR-223) was highly pancreas-specific and liver-specific. miR-30e was downregulated in patients with type 2 diabetes, while miR-92a was downregulated in animal models of diabetes. In sensitivity analysis, 40 out of 47 miRNAs (85%) were robustly and consistently dysregulated. CONCLUSIONS/ INTERPRETATION: This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375, miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
Authors: M Balasubramanyam; S Aravind; K Gokulakrishnan; P Prabu; C Sathishkumar; H Ranjani; V Mohan Journal: Mol Cell Biochem Date: 2011-01-20 Impact factor: 3.396
Authors: Sukrutha Chettimada; Hirotaka Ata; Dhwajbahadur K Rawat; Salil Gulati; Andrea G Kahn; John G Edwards; Sachin A Gupte Journal: Am J Physiol Heart Circ Physiol Date: 2013-11-08 Impact factor: 4.733
Authors: Matthew N Poy; Jean Hausser; Mirko Trajkovski; Matthias Braun; Stephan Collins; Patrik Rorsman; Mihaela Zavolan; Markus Stoffel Journal: Proc Natl Acad Sci U S A Date: 2009-03-16 Impact factor: 11.205
Authors: Sung-Ji Yun; Eun-Kyoung Kim; David F Tucker; Chi Dae Kim; Morris J Birnbaum; Sun Sik Bae Journal: Biochem Biophys Res Commun Date: 2008-04-16 Impact factor: 3.575
Authors: B M Herrera; H E Lockstone; J M Taylor; M Ria; A Barrett; S Collins; P Kaisaki; K Argoud; C Fernandez; M E Travers; J P Grew; J C Randall; A L Gloyn; D Gauguier; M I McCarthy; C M Lindgren Journal: Diabetologia Date: 2010-03-03 Impact factor: 10.122
Authors: Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan Journal: PLoS One Date: 2011-08-01 Impact factor: 3.240
Authors: Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn Journal: Cell Metab Date: 2019-08-22 Impact factor: 27.287
Authors: Silvana Debernardi; Nathalie J Massat; Tomasz P Radon; Ajanthah Sangaralingam; Ana Banissi; Darren P Ennis; Thomas Dowe; Claude Chelala; Stephen P Pereira; Hemant M Kocher; Bryan D Young; Giles Bond-Smith; Robert Hutchins; Tatjana Crnogorac-Jurcevic Journal: Am J Cancer Res Date: 2015-10-15 Impact factor: 6.166